Triple wild-type (KRAS, BRAF, and NRAS) CRC respond to anti-EGFR monoclonal antibodies in combination with chemotherapy [5], whereas the occurrence of BRAF p.Val600Glu mutation opens the window for a combination with BRAF inhibitors [6,7]. This evidence concerns the gene BRAF and colorectal carcinoma.